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Abstract
Introduction: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9
(TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Because TLR9 signaling plays an important role in systemic
lupus erythematosus (SLE), we investigated whether PGRN is involved in the pathogenesis of SLE.
Methods: We measured concentrations of serum PGRN and interleukin-6 (IL-6) with enzyme-linked
immunosorbent assay (ELISA) in patients with SLE (n = 68) and in healthy controls (n = 60). We assessed the
correlation between the serum PGRN levels and established disease-activity indexes. The sera from the patients
with high PGRN titers (>80 ng/ml) at the initial evaluation were reevaluated after the disease was ameliorated by
treatment. We also measured the IL-6 concentration secreted by peripheral blood mononuclear cells (PBMCs)
incubated with (a) oligonucleotide (CpG-B) in the presence or absence of recombinant human PGRN (rhPGRN); and
(b) lupus sera in the presence or absence of a neutralizing anti-PGRN antibody.
Results: Serum PGRN levels were significantly higher in SLE patients than healthy controls. Their levels were
significantly associated with activity of clinical symptoms. They also significantly correlated with values of clinical
parameters, including the SLE Disease Activity Index and anti-double-stranded DNA antibody titers, and inversely
with CH50, C3, and C4 levels. Moreover, serum PGRN levels significantly decreased after successful treatment of
SLE. The rhPGRN significantly upregulated the production of IL-6 by PBMCs stimulated with CpG-B. Patients’ sera
stimulated production of IL-6 from PBMCs, which was significantly impaired by neutralization of PGRN. The serum
PGRN levels significantly correlated with the serum IL-6 levels.
Conclusions: Serum PGRN could be a useful biomarker for disease activity of SLE. PGRN may be involved in the
pathogenesis of SLE partly by enhancing the TLR9 signaling.
Introduction
Systemic lupus erythematosus (SLE) is a systemic auto-
immune and inflammatory disease characterized by the
polyclonal activation of T and B lymphocytes, produc-
tion of autoantibodies, and formation of immune com-
plexes that result in tissue and organ damage [1,2].
Toll-like receptor (TLR) signaling contributes to
innate and adaptive immune responses [3]. TLR9 is a
receptor for microbial CpG-DNA [4] and is expressed in
plasmacytoid dendritic cells (pDCs), macrophages, and
B-lymphocytes [5]. TLR9 recognizes unmethylated CpG
oligonucleotides (CpG-ODNs), which are generally not
present in mammalian cells [6]. However, in SLE,
nucleic acid-containing autoantigens can be generated
from apoptotic or necrotic cells [7] because of increased
apoptosis, reduced clearance of apoptotic cells [8], and
decreased methylation of DNA [9]. Patients with active
SLE have increased TLR9 expression in peripheral blood
memory and plasma B lymphocytes [10], and TLR9 sig-
naling controls anti-DNA autoantibody production from
these B cells in murine [11] and human lupus [12]. A
genetic variation of TLR9 is associated with an increased
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risk of SLE [13]. These lines of evidence suggest that
TLR9 signaling may play an important role in the
pathogenesis of SLE.
Progranulin (PGRN; GenBank: NC_000017) is an
extracellular glycoprotein, containing seven and a half
repeats of cysteine-rich motifs. PGRN is proteolytically
cleaved by extracellular proteases, such as proteinase 3
(PR3) and elastase, into granulin (GRN) [14], which
ranges from 6 to 25 kDa. PGRN is abundantly expressed
in rapidly cycling epithelial cells, leukocytes, chondro-
cytes, and neurons [15], and its expression level is at
steady state [16]. PGRN plays a critical role in early
embryogenesis [16], wound healing [17], maintenance of
neuronal survival [18], and tumorigenesis [15]. Recent
mouse studies show that mice unable to convert PGRN
into GRN because of lack of both elastase and PR3 can-
not show inflammation in response to injection of
immune complexes [19]. These data indicate that PGRN
is rapidly cleaved into GRNs in tissues by elastase to
enhance inflammation. Moreover, GRN acts as a soluble
cofactor for TLR9 signaling by binding to both CpG-
ODNs and TLR9, thereby acting as a cross-linker for
their interaction. GRN also promotes the delivery of
CpG-ODNs to the endolysosomal compartments where
TLR9 is localized [20].
Here, we show that serum PGRN levels are signifi-
cantly elevated in SLE patients in parallel with disease
activities and that PGRN may have a role in the patho-




We performed a cross-sectional study of patients who
were treated for SLE at the Kyushu University hospital
between the years of 2005 and 2011. In total, 68 Japa-
nese patients with SLE were enrolled, and sera were
obtained from these patients. All of the patients fulfilled
at least four of the American College of Rheumatology
(ACR) revised criteria for SLE. SLE disease activity was
measured by using the SLE Disease Activity Index (SLE-
DAI) [21]. Active SLE was defined as a SLEDAI score
≥6 [21]. We excluded other autoimmune and infectious
diseases. Each patient completed a standardized medical
history, including drug use, and was given a physical
examination. Serologic profiling of each patient was per-
formed by using the standard immunoassays described
later. The serum samples from the active SLE patients
were acquired before the initiation or reinforcement of
treatment, and the samples from the inactive SLE
patients were acquired during regular hospital visits and
then stored at -20°C.
The active SLE patients were treated with corticoster-
oids or immunosuppressive drugs after the completion
of these evaluations. The sera obtained from the patients
with high PGRN titers (>80 ng/ml) at the initial evalua-
tion were reevaluated after the disease was ameliorated
by treatment (n = 15). Control sera were obtained from
healthy staff members (n = 60) in our hospital. This
study was approved by the ethics committee of our
institution, and the principles of the Helsinki Declara-
tion were followed throughout the study. Informed con-
sent was obtained from all participants.
Data collection
The information obtained from the medical records of
the patients included demographic data, such as age, sex,
clinical manifestations of SLE, and laboratory values.
Each SLE-related feature except anemia was defined
according to the SLEDAI. Clinical features checked were
malar rash/discoid rash, alopecia, oral or nasal ulcers,
serositis, arthritis, active nephritis, CNS (central nervous
system) lupus, vasculitis, fever >38°C, thrombocytopenia,
leukopenia, and anemia. For example, thrombocytopenia
was defined as a decrease in the number of platelets to
<100,000/mm3. Leukopenia was defined as a decrease in
the number of white blood cells to <3,000/mm3. Anemia
was defined as a decrease in the concentration of hemo-
globin to <10.0 g/dl for any cause. The data for the
serum anti-Smith (anti-Sm), anti-ribonucleoprotein (anti-
nRNP), anti-Ro/SS-A (anti-Ro), and anti-cardiolipin
(anti-CL) antibodies were collected only from active SLE
patients in whom these autoantibodies were measured
(anti-Sm, n = 42; anti-nRNP, n = 35; anti-Ro, n = 39; and
anti-CL, n = 44).
The measurement of complement and autoantibody
levels
The serum C3 and C4 levels were measured with turbi-
dimetric immunoassay (Nittobo, Tokyo, Japan). The
serum CH50 levels were measured with liposome immu-
nosorbent assay (Wako, Tokyo, Japan). The serum anti-
dsDNA, anti-Sm, anti-nRNP, and anti-Ro antibody levels
were measured by using fluorescence-enzyme immu-
noassay (Phadia, Tokyo, Japan). The serum anti-CL anti-
body levels were measured with ELISA (MBL, Nagano,
Japan).
Immunoprecipitation
A primary antibody for PGRN (anti-PGRN Ab; R&D
Systems, Minneapolis, MN, USA) or an isotype control
antibody (control Ab; R&D Systems) was added to pro-
tein G-Sepharose (Pierce, Rockford, IL, USA) in phos-
phate-buffered saline (PBS) with 0.5% Triton-X and
incubated on a shaker for 4 hours at 4°C. Recombinant
human PGRN (rhPGRN; Cedarlane, Burlington, NC,
USA) was added to the anti-PGRN Ab- or control Ab-
protein G-Sepharose complexes and incubated on a
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shaker for 4 hours at 4°C. After washing the complexes,
the proteins were eluted by boiling in sample buffer
(0.125 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 3.1%
dithiothreitol, and bromophenol blue). Proteins were
separated by sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred onto a nitrocel-
lulose membrane, blocked with 5% skim milk in PBS
with 0.1% Tween-20 for 1 hour, and probed with
another anti-PGRN Ab (Epitomics, Burlingame, CA,
USA) overnight at 4°C. The membranes were washed
and incubated with horseradish peroxidase-conjugated
streptavidin (Pierce) for 1 hour. The immunoblots were
visualized with ECL detection reagent (Pierce).
IL-6 induction
Peripheral blood mononuclear cells (PBMCs; 4 × 105
cells) from healthy control individuals were cultured
with 250 ng/ml rhPGRN in serum-free medium (Invitro-
gen, Grand Island, NY, USA) for 2 hours to let PGRN
partially convert into GRNs and were then stimulated
with 10 nM CpG-B, 100 ng/ml poly (I:C) (agonist for
TLR3) (InvivoGen, San Diego, CA, USA), 60 pg/ml LPS
(agonist for TLR4) (Sigma-Aldrich, Saint Louis, MO,
USA), or 1 µg/ml imiquimod (R837; agonist for TLR7)
(InvivoGen). The PBMCs were also stimulated with 10%
serum from SLE patients (n = 4) in the presence of
anti-PGRN Ab or control Ab. In some experiments,
lupus sera (n = 3) were treated for 1 hour with 6,000 U/
ml DNase I (Roche, Penzberg, Germany) before stimula-
tion. Triplicate cultures were grown in 96-well plates
(Becton Dickinson, Franklin Lakes, NJ, USA) at a final
volume of 200 µl/well. After 24 hours, the amount of
IL-6 in the supernatant was measured.
Measurement of PGRN, IL-6, IL-10, and immune
complexes
The serum PGRN levels, serum and cell-culture super-
natant IL-6 and IL-10 levels were determined by using
ELISA kits (R&D Systems) according to the manufac-
turer’s protocol. In brief, for PGRN, calibrators, control
sera, and patients’ sera (stored samples) were diluted
and incubated with a mouse monoclonal antibody
against PGRN, adsorbed onto the microtiter plate wells.
After washing, a mouse monoclonal antibody against
PGRN conjugated to horseradish peroxidase was added,
followed by a second washing step and the addition of
tetramethylbenzidine substrate. The intensity of the blue
color developed was in proportion to the amount of
PGRN bound in the initial step. The reaction was termi-
nated by the addition of 2N sulfuric acid. The absor-
bance was measured in a microtiter plate reader
(ThermoFisher Scientific, Waltham, MA, USA) and con-
verted into nanograms per milliliter by plotting the
values against the PGRN titer of the calibrators/
standards given by the manufacturer. The assay range
was 1.56 to 100 ng/ml.
Serum levels of immune complexes were measured
with C1q solid-phase enzyme immunoassay according to
the manufacturer’s protocol (TFB, Tokyo, Japan).
Statistical analysis
The differences between two groups were analyzed by
using the Student t test. If there were a significant dif-
ference between the variances of the two samples, the t
test corrected for unequal variances (the Welch t test)
was applied. The Dunnett test is used for multiple com-
parisons with a control group. The relations between
PGRN levels and other continuous variables were ana-
lyzed by using the Spearman rank correlation. The
PGRN levels before and after treatment were compared
by using a paired t test. The SLE patients were divided
into three groups based on tertile distribution of the
number of clinical features (0, 1 to 2, and 3 to 8). Linear
trend across the tertiles was assessed by using ordinal
variables coded 1 to 3. Among three groups, P values
were calculated by analysis of variance and were
adjusted by use of the Bonferroni correction. P values
<0.05 were considered significant. All tests were two-
tailed. All analyses were performed by using JMP statis-
tical software (SAS Institute).
Results
The serum PGRN levels were elevated in patients with
SLE
Of the 68 patients with SLE enrolled in the present study,
58 were women, and 10 were men (active, n = 46; inac-
tive, n = 22). The patients ranged in age from 17 to 76
years (median age, 37 years). Meanwhile, in healthy con-
trols, 51 were women, and nine were men. They ranged
in age from 20 to 59 years (median age 32 years). No sig-
nificant differences were found between patients with
SLE and controls in terms of age and gender.
To investigate the role of PGRN and/or GRN in the
pathogenesis of SLE, we first compared serum PGRN
levels between 68 patients with SLE and 60 healthy con-
trols by using ELISA (Figure 1). Serum PGRN levels in
controls were always within the range of 35 to 70 ng/ml
and distributed normally. Serum PGRN levels in patients
with SLE (mean, 87.6 ng/ml) were significantly and
markedly higher than those in healthy controls (49.3 ng/
ml; P < 0.0001). It is of note that serum PGRN levels
>100 ng/ml were found in 19 of the 68 SLE patients
(27.9%), but never in healthy controls.
The serum PGRN levels in SLE patients correlated with
disease activities
We next tested whether serum PGRN levels correlate
with serologic parameters for disease activity of SLE.
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Serum PGRN levels showed a significantly positive cor-
relation with SLEDAI (rs = 0.53; P = 0.0003; Figure 2A).
They also significantly correlated with the titer of anti-
dsDNA antibodies (rs = 0.45; P = 0.0023; Figure 2B)
and inversely with serum levels of C3 (rs = -0.41; P =
0.01; Figure 2C), C4 (rs = -0.37; P = 0.002; Figure 2D),
and CH50 (rs = -0.47; P = 0.0035; Figure 2E). Moreover,
in 15 lupus patients who had high serum PGRN levels
(>80 ng/ml) at the initial evaluation, after ameliorating
the disease by treatment, serum PGRN levels were sig-
nificantly decreased (P = 0.0001; Figure 3). Serum
PGRN levels reflected disease activities of SLE.
The high serum PGRN levels were associated with the
accumulation of the clinical features of SLE
We next investigated the relation between SLE-related
clinical features and serum PGRN levels. Patients who
had positive levels of anti-nRNP antibodies showed sig-
nificantly elevated levels of serum PGRN (P = 0.002;
Table 1). The maximum number of coexisting clinical
features was eight (n = 1). When classified by the
number of clinical features, serum PGRN levels elevated
significantly, with increasing tertile of clinical feature
(Table 1, P for trend = 0.005). Thus, the high serum
PGRN levels were associated with the accumulation of
the clinical features of SLE.
PGRN is involved in the production of IL-6 from human
PBMCs
GRN enhances the CpG-induced TLR9 signaling (not
TLR 3, 4, or 7 signaling) and promotes the production of
IL-6, an inflammatory cytokine related to the pathogen-
esis of SLE, in murine macrophages [20]. Accordingly, we
tested whether PGRN is involved in secretion of IL-6 via
TLR9 signaling by human PBMCs. In the lupus model
mouse, TLR 3, 4, 7, and 9 signaling are reported to be
involved in the pathogenesis of lupus [22-24]. PBMCs
from healthy controls were incubated with 10 nM (sub-
optimal concentration in our case; data not shown) CpG-
B, 60 pg/ml LPS, 100 ng/ml poly (I:C), or 1 µg/ml imiqui-
mod for 24 hours with or without 250 ng/ml rhPGRN.
This rhPGRN concentration is slightly lower than the
PGRN concentration we found in patients’ sera (Figure 1).
The addition of rhPGRN to the culture media signifi-
cantly stimulated PBMCs to produce IL-6 in the presence
of CpG-B (P < 0.05; Figure 4A). However, IL-6 production
induced by rhPGRN was not augmented in the presence
of poly (I:C), LPS, or imiquimod (Figure 4A), as previously
reported [20]. Lupus serum contains immune complexes
and is able to induce the production of IL-6 and IL-10
from PBMCs [25,26]. Actually, immune complexes were
present in patients’ sera we used (Patients 1 through 7,
median, 6.1 µg/ml; range, 2.6 to 9.7 µg/ml). Those levels
in healthy controls (n = 7) were less than 1.5 µg/ml. Con-
sistent with the previous reports, by incubation with
patients’ sera, PBMCs from healthy controls were stimu-
lated to produce considerable amounts of IL-6 and IL-10
(Figure 4B, and data not shown).
We then tested whether this stimulation of IL-6 and
IL-10 production is dependent on the PGRN contained
in patients’ sera. To this end, we used an anti-PGRN
antibody that can bind to PGRN demonstrated by
immunoprecipitation and immunoblot analyses (Figure
4B, bottom). We incubated PBMCs with 10% patients’
sera supplemented with the anti-PGRN Ab or with the
control Ab for 24 hours. The neutralization of PGRN
significantly impaired the effect of patients’ sera on IL-6
production from normal PBMCs (P < 0.05) in all four
cases tested (Figure 4B, top; reduction range, 42.8% to
84%). Although IL-10 production tended to be reduced
by the neutralization of PGRN, the level of reduction
was not significant (data not shown).
We then tested whether TLR9 signaling is involved in
this reduction of IL-6 production by neutralizing the
Figure 1 The serum progranulin (PGRN) levels are elevated in
patients with systemic lupus erythematosus (SLE). Serum PGRN
levels in 68 patients with SLE and 60 healthy controls (HCs) are
shown, as measured with enzyme-linked immunosorbent assay
(ELISA). The serum PGRN levels in SLE patients were significantly
higher than those in HCs.
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PGRN contained in patients’ sera. To this end, we treated
lupus sera (n = 3) with 6,000 U/ml DNase I for 1 hour
before stimulation. The degradation of DNA significantly
impaired the effect of patients’ sera on IL-6 production
from normal PBMCs. The degree of suppression was
almost as same as that caused by the neutralization of
PGRN (P < 0.05; Figure 4C).
We further examined the correlation between concen-
trations of PGRN and IL-6 in patients’ sera. As expected,
serum PGRN levels showed a significantly positive corre-
lation with serum IL-6 levels (rs = 0.47; P < 0.0001;
Figure 4D). These results suggest that serum PGRN and/
or GRN is an important cofactor in the production of IL-
6 in SLE patients.
Discussion
This is the first study to show that PGRN levels are sig-
nificantly elevated in sera of SLE patients, and their con-
centrations were correlated with disease activity and
serum levels of IL-6. Thus, PGRN and/or GRN in
patients’ sera play an important role in the production
of IL-6 from PBMCs.
PGRN is produced by various types of cells [15], but
the mechanism of the expression control of PGRN is not
well understood. In humans, the elevation of PGRN is
observed in local inflammatory tissues, such as in brains
in patients with active multiple sclerosis [27] and in the
synovium of rheumatoid arthritis (RA) patients [28]. We
measured concentrations of serum PGRN in patients
Figure 2 The serum progranulin (PGRN) levels in systemic lupus erythematosus (SLE) patients correlate with disease activities.
Correlations are shown between the serum PGRN levels and the SLEDAI scores, the titers of (A) anti-dsDNA antibody (anti-dsDNA Ab) (B), the
serum levels of C3 (C), C4 (D), and CH50 (E), as measured in 68 patients with SLE. For all comparisons, significant positive or negative
correlations were observed.
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with RA (n = 33). In our data, although sera from RA
patients contained significantly elevated PGRN (mean,
54.7 ng/ml) compared with healthy controls (P = 0.0138),
SLE patients’ sera had much higher levels of PGRN.
PGRN is converted to GRN by the elastase produced
by leukocytes and other cells in vivo and in vitro [29].
In contrast to that with PGRN, recent mouse studies
have shown that GRN possess inflammatory functions
[19,30,31]. Because we cannot measure serum GRNs, it
is difficult to investigate the function of GRN in human
studies.
Our data also show that rhPGRN enhances IL-6 pro-
duction from human PBMCs in the presence of TLR9
signaling triggered by CpG, but does not enhance TLR3,
4, or 7 signaling (Figure 4A). In addition, patients’ sera
stimulated PBMCs to produce IL-6, whereas neutraliza-
tion of PGRN in patients’ sera dramatically attenuated
such IL-6 production from PBMCs, almost the same as
the degradation of DNA in patients’ sera (Figure 4B and
4C). IL-6 production in lupus is reported to mediate by
immune complexes that transmit signals through TLR7
and 9 [22,32-34] and Fcg receptor [26]. Our data suggest
that DNA-containing immune complexes in patients’
sera stimulate IL-6 production from healthy PBMCs,
mainly via TLR9 signaling, and that serum PGRN and/
or GRN may act as an important cofactor of TLR9 sig-
naling. Conversely, because the augmentation of IL-6
production induced by CpG only in the presence of
rhPGRN was limited, it is suggested that cofactors other
than PGRN may be required to form immune com-
plexes that effectively stimulate TLR9 signaling.
In our analysis, serum PGRN levels were significantly
correlated with serum titers of anti-dsDNA and anti-
nRNP antibodies. IL-6 plays a role in patients with SLE,
especially on the production of immunoglobulin [35-39].
In addition, lupus B lymphocytes are hypersensitive to
IL-6 [40,41]. Thus, induction of IL-6 by PGRN and/or
GRN could be a mechanism by which PGRN is corre-
lated with the production of these autoantibodies.
Figure 3 Serum progranulin (PGRN) levels are significantly
decreased after ameliorating the disease with treatment. Serum
PGRN levels before and after treatment in 15 patients with active
systemic lupus erythematosus (SLE) who had serum PGRN levels
>80 ng/ml at the initial evaluation. The serum PGRN levels
decreased significantly with the clinical amelioration of the disease
from the median SLEDAI score of 11 to 4 after treatment.
Table 1 Associations between systemic lupus erythematosus (SLE)-related serologic and clinical features and titer of
progranulin (PGRN)
Feature Number Mean PGRN (95% confidence interval) P
Positivea Negativea
Serologic featureb Positive/negative
Anti-Sm 25/17 111.8 (93.4-130.1) 94.1 (56.5-131.7) 0.381c
Anti-nRNP 23/12 128.9 (102.7-155.0) 74.9 (53.5-96.3) 0.002c
Anti-Ro 26/13 102.7 (79.6-125.8) 105.6 (67.6-143.6) 0.888
Anti-CL 20/24 112.4 (84.0-140.8) 87.4 (65.2-109.6) 0.150
Clinical featuresd
0 22 51.3 (34.5-68.1) <0.001ef
1-2 31 91.8 (81.1-102.5) <0.001e
3-8 15 132.3 (113.1-151.5) 0.005g
anti-Sm, anti-Smith antibody; anti-nRNP, anti-ribonucleoprotein antibody; anti-Ro, anti-Ro/SS-A antibody; anti-CL, anti-cardiolipin antibody. aSLE patients with
(present) or without (absent) the clinical features of SLE. bSeveral observations with missing values. cWelch t test. dNumber of positive clinical features including
malar rash/discoid rash, alopecia, oral or nasal ulcers, serositis, arthritis, active nephritis, CNS (central nervous system) lupus, vasculitis, temperature >38°C,
thrombocytopenia, leukopenia, anemia. eAs compared with three to eight clinical features (one-way analysis of variance followed by the Bonferroni test). fAs
compared with one to two clinical features (one-way analysis of variance followed by the Bonferroni test). gP for trend.
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Interestingly, anti-Ro antibody, which is strongly asso-
ciated with increased interferon-pathway activation in
SLE [42], was not associated with serum PGRN levels,
indicating that PGRN may be involved in the pathogen-
esis of SLE, independent of the interferon pathway. In
addition, serum PGRN levels were significantly elevated
with increasing clinical features. Individually, serum
PGRN levels were significantly higher in the SLE
patients who developed dominant clinical features,
namely anemia (P = 0.019, data not shown) and arthritis
(P = 0.002, data not shown). The elevated IL-6 and
enhanced inflammation could accelerate these clinical
features. IL-6 impairs iron utilization, leading to anemia
of chronic disease. In addition, IL-6 promotes arthritis
in patients with SLE [37]. Thus, the induction of IL-6
via PGRN is a possible explanation for the fact that
PGRN levels are correlated with anemia and arthritis.
We must acknowledge some limitations of this study.
The sample size of our study was small. Statistical tests
usually require a larger sample size to justify that the
effect did not happen by chance alone. Moreover,
because of its cross-sectional design, it is difficult to
establish the exact and definite causal relations, except
the association between PGRN and development of SLE
from the collected data.
In conclusion, this pilot study demonstrated that the
serum PGRN levels were elevated in patients with SLE
and were associated with the systemic disease activity.
PGRN could be a useful biomarker for disease activity
and may be involved in the pathogenesis of SLE, partly
by enhancing the TLR9 signaling. Further studies are
required to reveal more-precise mechanisms of PGRN
and GRN in human autoimmune diseases and in host
defense against microbes.
Figure 4 Progranulin (PGRN) and/or its fragments GRNs augment the IL-6 production by human peripheral blood mononuclear cells
(PBMCs) via TLR9 signaling. (A) PBMCs from healthy control individuals were incubated for 24 hours in serum-free medium with or without
10 nM CpG-B, 100 ng/ml poly (I:C), 60 pg/ml LPS, or 1 µg/ml imiquimod and purified PGRN (250 ng/ml). The supernatant IL-6 levels were
measured with ELISA. The data are representative of three independent experiments (average and SEM). (B, C) The binding of anti-PGRN Ab to
PGRN was verified by immunoprecipitation and immunoblot with anti-PGRN Ab. In C, lupus sera were partly treated for 1 hour with 6,000 U/ml
DNase I before stimulation. The PBMCs were then incubated in serum-free medium or were stimulated with 10% serum from systemic lupus
erythematosus (SLE) patients in the presence of anti-PGRN Ab or control Ab for 24 hours. The supernatant IL-6 levels were measured with ELISA.
(D) The serum PGRN levels correlated significantly with the serum IL-6 levels in SLE patients. *P < 0.05.
Tanaka et al. Arthritis Research & Therapy 2012, 14:R244
http://arthritis-research.com/content/14/6/R244
Page 7 of 9
Conclusions
The present study demonstrated that the serum levels of
PGRN, a fragment of which (GRN) is a soluble cofactor
for TLR9 signaling, were elevated in patients with SLE
and were associated with the systemic disease activity.
PGRN may have a role in the pathogenesis of SLE,
partly by affecting TLR9 signaling, and could be a useful
biomarker for disease activity. These findings provide
new insights into the pathogenesis as well as the therapy
of SLE, and shed new light on the dysregulation of the
immune system in autoimmune diseases.
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